Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)

Fig. 2

Patient disposition. AE adverse event. aLack of efficacy (n = 1); did not meet inclusion criteria/protocol deviation (n = 1); bElective bone marrow transplantation (n = 1); could not attend study visits or comply with treatment application (n = 1)

Back to article page